By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit St.
Science Park
Carmiel      Israel
Phone: 972-4-9028100 Fax: 972-4-988-9489


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA 11/16/2015 7:42:07 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Third Quarter 2015 Financial Results 11/10/2015 8:02:38 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Long Term Data On PRX-102 For Fabry Disease 10/19/2015 7:28:44 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At The Rodman & Renshaw 16th Annual Global Investment Conference 9/4/2014 10:10:13 AM
Pfizer Inc. (PFE) And FDA Announce Protalix Biotherapeutics, Inc. (PLX) Approval Of Pediatric Indication For ELELYSO™ (taliglucerase alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease 8/29/2014 11:00:08 AM
Protalix Biotherapeutics, Inc. (PLX)' Technology Transfer Agreement For UPLYSO™ (Alfataliglicerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property 2/6/2014 9:30:49 AM
Protalix Biotherapeutics, Inc. (PLX) Signs $280 Million Brazilian Gaucher Deal 6/19/2013 7:35:13 AM
Protalix Biotherapeutics, Inc. (PLX) to Present at the Oppenheimer 14th Annual Israeli Conference 5/8/2013 9:29:09 AM
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease 4/2/2013 11:39:12 AM
Protalix Biotherapeutics, Inc. (PLX) Signs $8.3 Million Deal With Pfizer Inc. (PFE) to Continue Managing Elelyso Trials 12/6/2012 7:14:17 AM
12
//-->